Original paper
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity
Abstract
Anti-CD52 therapy has been shown to be effective in the treatment of a number of B cell malignancies, hematopoietic disorders and autoimmune diseases (including rheumatoid arthritis and multiple sclerosis); however the current standard of treatment, the humanized monoclonal antibody alemtuzumab, is associated with the development of anti-drug antibodies in a high proportion of patients. In order to address this problem, we have identified a...
Paper Details
Title
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity
Published Date
Sep 15, 2015
Journal
Volume
10
Issue
9
Pages
e0138123 - e0138123
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History